Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longboard Pharmaceuticals reports robust financials and optimistic pipeline outlook

Longboard Pharmaceuticals showcases strong financial position and operational support.
Emphasis on unique characteristics and market opportunities of pipeline assets.
Addressing challenges in patient care and market competition for growth.
Optimism and anticipation for future data outcomes and market performance.

Longboard Pharmaceuticals excels in Q2 with breakthrough therapies and strong financial position

Longboard Pharmaceuticals demonstrated strong performance in Q2 2024, with positive data for Bexicaserin and regulatory milestones enhancing their market position.
The company's strengths lie in the success of their lead assets, financial stability, and strategic focus on addressing key market needs.
Challenges include transitioning preclinical success to clinical efficacy, regulatory hurdles, market competition, and maintaining innovation while ensuring compliance.
Opportunities include market expansion through Breakthrough Therapy designation, advancing LP659, leveraging financial strength for growth, and strategic market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data at the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress which is taking place in Rome, Italy from September 7-11, 2024. “ILAE is one of the premier medical organizations in the epilepsy space and we look forward to.

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist in development for the treatment of seizures associated with Developmental and Epi.

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securities Joel Beatty - Baird Gavin Clark-Gartner - Evercore Kalpit Patel - B. Riley Securities David Hoang - Citigroup Yatin Suneja - Guggenheim Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Update Call.

Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported second quarter 2024 financial results. “The first half of the year has been monumental for Longboard and underpins the vision that we have been working towards since the inception of the Company, which is to help a broad range of patients living.

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a con.

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why

Avidity Biosciences

SoundHound AI Inc

Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

The mean of analysts' price targets for Longboard Pharmaceuticals (LBPH) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet

Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable

Harrow Health Inc

Eli Lilly

As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Crash This Quarter

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. “We are thrilled to receive Breakthroug.

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #5HT2--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies. “We are thrilled to see a sustained, durable response in seizure.

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results. “I am extremely encouraged by the totality of the bexicaserin data generated to date. The recently presented late-breaking data from the PACIFIC Study at AAN continues to support the potential of bexicaserin.

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard's Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN.

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results. “I am extremely proud of what our team has accomplished starting with the immense effort that went into the PACIFIC Study in participants with DEEs. We are impressed with the data in this study showing evidence.

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February. Conference Details: Event: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Details: Presenting in a fireside chat format on Wednesday, February 7, 2024, a.

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

Longboard Pharmaceuticals stock is up nearly 300% barely two weeks into the new year. The massive gain came after the company reported positive clinical results for its lead pipeline candidate.

Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares.

Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why

As the market continues to witness a resurgence in small-cap investments, led by a jump in investor optimism and speculation, there's been a seemingly steady flow of capital back into traditionally riskier sectors.

This biotech stock has surged over 300% this week

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offeri.

Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.

Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $150 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchas.

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Clinical-stage biopharmaceutical firm Longboard Pharmaceuticals (NASDAQ: LBPH ) got the new year off to the best start possible with a dramatic run. Earlier Tuesday morning, management disclosed positive topline data for its therapeutic bexicaserin, which addresses seizures in patients with developmental and epileptic encephalopathies (DEEs).

News for Longboard Pharmaceuticals Stock (LBPH)